Erratum: A novel oncolytic adenovirus selectively silences the expression of tumor-Associated STAT3 and exhibits potent antitumoral activity (Carcinogenesis (2009) 30:12 (2014-2022) DOI: 10.1093/carcin/bgp249);A novel oncolytic adenovirus selectively silences the expression of tumor-associated STAT3 and exhibits potent antitumoral activity

Carcinogenesis

Volumn 30, Issue 12, 2009, Pages 2014-2022

  Han, Zhiqiang ^a   Hong, Zhenya ^a   Chen, Caihong ^a   Gao, Qinglei ^a   Luo, Danfeng ^a   Fang, Yong ^a   Cao, Yang ^a   Zhu, Tao ^a   Jiang, Xuefeng ^a   Ma, Quanfu ^a   Li, Wei ^a   Han, Lingfei ^a   Wang, Daowen ^a   Xu, Gang ^a   Wang, Shixuan ^a   Meng, Li ^a   Zhou, Jianfeng ^a   Ma, Ding ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; COMPLEMENTARY DNA; ONCOLYTIC VIRUS; STAT3 PROTEIN; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; COLLAGEN; LAMININ; MATRIGEL; PROTEOGLYCAN; STAT3 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL INVASION; CONTROLLED STUDY; DRUG EFFICACY; GENE EXPRESSION; GENE INSERTION; GENE SILENCING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STOMACH CARCINOMA; SURVIVAL TIME; TOXICITY TESTING; TUMOR CELL; VIRUS REPLICATION; ADENOVIRUS; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; BIOLOGICAL MODEL; CHEMISTRY; DRUG COMBINATION; GENETICS; MALE; METASTASIS; MUTATION; NEOVASCULARIZATION (PATHOLOGY); TUMOR CELL LINE;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; COLLAGEN; DRUG COMBINATIONS; GENE SILENCING; HUMANS; LAMININ; MALE; MICE; MICE, INBRED BALB C; MODELS, GENETIC; MUTATION; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDES, ANTISENSE; ONCOLYTIC VIRUSES; PROTEOGLYCANS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 73949086090     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgz202     Document Type: Erratum

References (36)

1. Darnell, J.E.Jr (1997) STATs and gene regulation. Science, 277, 1630-1635.
2. Bromberg, J. et al. (2000) The role of STATs in transcriptional control and their impact on cellular function. Oncogene, 19, 2468-2473.
3. Bromberg, J. (2000) Signal transducers and activators of transcription as regulators of growth, apoptosis and breast development. Breast Cancer Res., 2, 86-90.
4. Smithgall, T.E. et al. (2000) Control of myeloid differentiation and survival by Stats. Oncogene, 19, 2612-2618.
5. Rawlings, J.S. et al. (2004) The JAK/STAT signaling pathway. J. Cell Sci., 117, 1281-1283.
6. Yu, H. et al. (2004) The STATs of cancer-new molecular targets come of age. Nat. Rev. Cancer, 4, 97-105.
7. Groner, B. et al. (2008) The function of Stat3 in tumor cells and their microenvironment. Semin. Cell Dev. Biol., 19, 341-350.
8. Turkson, J. et al. (2000) STAT proteins: novel molecular targets for cancer drug discovery. Oncogene, 19, 6613-6626.
9. Buettner, R. et al. (2002) Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin. Cancer Res., 8, 945-954.
10. Wang, T. et al. (2004) Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med., 10, 48-54.
11. Al Zaid Siddiquee, K. et al. (2008) STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res., 18, 254-267.
12. Chen, Z. et al. (2008) STAT3: a critical transcription activator in angiogenesis. Med. Res. Rev., 28, 185-200.
13. Grandis, J.R. et al. (2000) Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc. Natl Acad. Sci. USA, 97, 4227-4232.
14. Niu, G. et al. (2002) Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene, 21, 2000-2008.
15. Darnell, J. (2005) Validating Stat3 in cancer therapy. Nat. Med., 11, 595-596.
16. Costantino, L. et al. (2008) STAT3 as a target for cancer drug discovery. Curr. Med. Chem., 15, 834-843.
17. Schust, J. et al. (2006) Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem. Biol., 13, 1235-1242.
18. Iwamaru, A. et al. (2007) A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene, 26, 2435-2444.
19. Xu, X. et al. (2009) Chemical probes that competitively and selectively inhibit STAT3 activation. PLoS One, 4, e4783.
20. Hermiston, T. (2000) Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer. J. Clin. Invest., 105, 1169-1172.
21. Mathis, J.M. et al. (2005) Oncolytic adenoviruses-selective retargeting to tumor cells. Oncogene, 24, 7775-7791.
22. Rein, D.T. et al. (2006) Current developments in adenovirus-based cancer gene therapy. Future. Oncol., 2, 137-143.
23. Kanerva, A. et al. (2005) Adenoviruses for treatment of cancer. Ann. Med., 37, 33-43.
24. Kay, M.A. et al. (2001) Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat. Med., 7, 33-40.
25. Zhou, J. et al. (2005) Novel oncolytic adenovirus selectively targets tumorassociated polo-like kinase 1 and tumor cell viability. Clin. Cancer Res., 11, 8431-8440.
26. Gao, Q. et al. (2006) Selective targeting of checkpoint kinase 1 in tumor cells with a novel potent oncolytic adenovirus. Mol. Ther., 13, 928-937.
27. Hawkins, L.K. et al. (2001) Gene delivery from the E3 region of replicating human adenovirus: evaluation of the ADP region. Gene Ther., 8, 1132-1141.
28. McGettrick, H.M. et al. (2006) Chemokine-and adhesion-dependent survival of neutrophils after transmigration through cytokine-stimulated endothelium. J. Leukoc. Biol., 79, 779-788.
29. Zhou, W. et al. (2006) STAT3 is required but not sufficient for EGF receptor-mediated migration and invasion of human prostate carcinoma cell lines. Br. J. Cancer, 95, 164-171.
30. Huang, X. et al. (2008) Biodistribution and kinetics of the novel selective oncolytic adenovirus M1 after systemic administration. Mol. Cancer Ther., 7, 1624-1632.
31. Wold, W.S. et al. (1995) E3 transcription unit of adenovirus. Curr. Top. Microbiol. Immunol., 199, 237-274.
32. Horwitz, M. (2004) Function of adenovirus E3 proteins and their interactions with immunoregulatory cell proteins. J. Gene Med., 6, 172-183.
33. Teodoro, J. et al. (1997) Regulation of apoptosis by viral gene products. J. Virol., 71, 1739-1746.
34. Yang, J. et al. (2005) Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res., 65, 939-947.
35. Lassmann, S. et al. (2007) STAT3 mRNA and protein expression in colorectal cancer: effects on STAT3-inducible targets linked to cell survival and proliferation. J. Clin. Pathol., 60, 173-179.
36. Khuri, F.R. et al. (2000) A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med., 6, 879 885.